The startup has developed a therapeutic platform that utilizes a combination of antibodies and small molecules to target specific proteins in the extracellular matrix, offering a more effective and less toxic alternative to traditional cancer treatments. This approach enables the targeting of a wide range of cancer types with a single therapeutic solution, addressing the limitations of existing cancer therapies.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer therapies lack specificity, leading to off-target effects and significant toxicity. Traditional treatments often fail to address the complex tumor microenvironment, limiting their effectiveness across diverse cancer types.
Solution
Matrisome Bio is developing a therapeutic platform that targets the extracellular matrix (ECM) to treat a wide range of cancers. Their approach combines antibodies and small molecules to selectively modulate the ECM, disrupting tumor support structures and enhancing drug delivery. By focusing on the tumor microenvironment rather than individual cancer cells, the platform aims to overcome resistance mechanisms and improve treatment outcomes. This strategy offers the potential for a more effective and less toxic alternative to conventional cancer therapies.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies focused on developing novel cancer therapeutics with improved efficacy and reduced toxicity.
Features
- Antibody-based therapeutics that target specific ECM proteins.
- Small molecule modulators designed to disrupt ECM structure and function.
- Platform approach applicable to a broad spectrum of cancer types.
- Enhanced drug delivery to tumor sites through ECM modulation.